Do analysts prefer NCNA or VTGN?

VistaGen Therapeutics has a consensus price target of $0.95, indicating a potential upside of 320.35%. Given VistaGen Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe VistaGen Therapeutics is more favorable than NuCana. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 VistaGen Therapeutics 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Is NCNA or VTGN more profitable?

NuCana has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -5,487.01%. VistaGen Therapeutics' return on equity of -133.02% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets NuCana N/A -153.61% -116.03% VistaGen Therapeutics -5,487.01% -133.02% -105.79%

Do analysts rate NCNA or BRNS?

Barinthus Biotherapeutics has a consensus price target of $4.00, suggesting a potential upside of 506.06%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than NuCana. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Barinthus Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is NCNA or BRNS more profitable?

Barinthus Biotherapeutics' return on equity of -63.83% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets NuCana N/A -153.61% -116.03% Barinthus Biotherapeutics N/A -63.83% -48.77%

Do analysts prefer NCNA or DYAI?

Dyadic International has a consensus target price of $3.00, suggesting a potential upside of 229.67%. Given Dyadic International's stronger consensus rating and higher probable upside, analysts clearly believe Dyadic International is more favorable than NuCana. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dyadic International 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Do analysts rate CPHI or NCNA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CPHI or NCNA more profitable?

NuCana has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets China Pharma -85.56% -63.93% -31.42% NuCana N/A -153.61% -116.03%

Do analysts recommend NCNA or BCTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NuCana 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, NCNA or BCTX?

NuCana is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NuCana N/A N/A -$38.71M -$2.98 N/A Briacell Therap N/A N/A -$26.31M -$7.92 N/A

Is NCNA or BCTX more profitable?

Briacell Therap's return on equity of -153.53% beat NuCana's return on equity. Company Net Margins Return on Equity Return on Assets NuCana N/A -153.61% -116.03% Briacell Therap N/A -153.53% -129.26%

NuCana (NCNA) Competitors

$1.52 -0.06 (-3.80%)

Closing price 04:00 PM Eastern

Extended Trading

$1.58 +0.06 (+3.95%)

As of 07:54 PM Eastern

Compare

NCNA vs. VTGN, BRNS, DYAI, CPHI, and BCTX

Should you buy NuCana stock or one of its competitors? MarketBeat compares NuCana with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NuCana include VistaGen Therapeutics (VTGN), Barinthus Biotherapeutics (BRNS), Dyadic International (DYAI), China Pharma (CPHI), and Briacell Therap (BCTX). These companies are all part of the "pharmaceutical products" industry.

How does NuCana compare to VistaGen Therapeutics?

NuCana (NASDAQ:NCNA) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

VistaGen Therapeutics has a consensus price target of $0.95, indicating a potential upside of 320.35%. Given VistaGen Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe VistaGen Therapeutics is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, VistaGen Therapeutics had 4 more articles in the media than NuCana. MarketBeat recorded 5 mentions for VistaGen Therapeutics and 1 mentions for NuCana. NuCana's average media sentiment score of 1.87 beat VistaGen Therapeutics' score of 0.93 indicating that NuCana is being referred to more favorably in the media.

Company	Overall Sentiment
NuCana	Very Positive
VistaGen Therapeutics	Positive

NuCana has higher earnings, but lower revenue than VistaGen Therapeutics. NuCana is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A
VistaGen Therapeutics	$1.27M	7.30	-$69.68M	-$1.83	N/A

NuCana has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -5,487.01%. VistaGen Therapeutics' return on equity of -133.02% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-153.61%	-116.03%
VistaGen Therapeutics	-5,487.01%	-133.02%	-105.79%

44.0% of NuCana shares are held by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are held by institutional investors. 31.2% of NuCana shares are held by company insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

NuCana has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Summary

VistaGen Therapeutics beats NuCana on 9 of the 14 factors compared between the two stocks.

How does NuCana compare to Barinthus Biotherapeutics?

NuCana (NASDAQ:NCNA) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

44.0% of NuCana shares are owned by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. 31.2% of NuCana shares are owned by insiders. Comparatively, 8.5% of Barinthus Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Barinthus Biotherapeutics' return on equity of -63.83% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-153.61%	-116.03%
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%

Barinthus Biotherapeutics has a consensus price target of $4.00, suggesting a potential upside of 506.06%. Given Barinthus Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Barinthus Biotherapeutics is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

NuCana has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market. Comparatively, Barinthus Biotherapeutics has a beta of -0.4, indicating that its share price is 140% less volatile than the broader market.

NuCana has higher earnings, but lower revenue than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A
Barinthus Biotherapeutics	$14.97M	1.80	-$66.43M	-$1.29	N/A

In the previous week, Barinthus Biotherapeutics had 1 more articles in the media than NuCana. MarketBeat recorded 2 mentions for Barinthus Biotherapeutics and 1 mentions for NuCana. NuCana's average media sentiment score of 1.87 beat Barinthus Biotherapeutics' score of 0.43 indicating that NuCana is being referred to more favorably in the media.

Company	Overall Sentiment
NuCana	Very Positive
Barinthus Biotherapeutics	Neutral

Summary

Barinthus Biotherapeutics beats NuCana on 8 of the 14 factors compared between the two stocks.

How does NuCana compare to Dyadic International?

NuCana (NASDAQ:NCNA) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Dyadic International has a consensus target price of $3.00, suggesting a potential upside of 229.67%. Given Dyadic International's stronger consensus rating and higher probable upside, analysts clearly believe Dyadic International is more favorable than NuCana.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Dyadic International had 3 more articles in the media than NuCana. MarketBeat recorded 4 mentions for Dyadic International and 1 mentions for NuCana. NuCana's average media sentiment score of 1.87 beat Dyadic International's score of 0.57 indicating that NuCana is being referred to more favorably in the media.

Company	Overall Sentiment
NuCana	Very Positive
Dyadic International	Positive

NuCana has a beta of 2.18, indicating that its share price is 118% more volatile than the broader market. Comparatively, Dyadic International has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

44.0% of NuCana shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 31.2% of NuCana shares are held by company insiders. Comparatively, 20.9% of Dyadic International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Dyadic International has higher revenue and earnings than NuCana. Dyadic International is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A
Dyadic International	$3.09M	10.73	-$7.36M	-$0.23	N/A

NuCana has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. NuCana's return on equity of -153.61% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-153.61%	-116.03%
Dyadic International	-192.40%	-1,005.45%	-77.64%

Summary

Dyadic International beats NuCana on 8 of the 15 factors compared between the two stocks.

How does NuCana compare to China Pharma?

China Pharma (NYSE:CPHI) and NuCana (NASDAQ:NCNA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

In the previous week, NuCana had 1 more articles in the media than China Pharma. MarketBeat recorded 1 mentions for NuCana and 0 mentions for China Pharma. NuCana's average media sentiment score of 1.87 beat China Pharma's score of 0.37 indicating that NuCana is being referred to more favorably in the news media.

Company	Overall Sentiment
China Pharma	Neutral
NuCana	Very Positive

China Pharma has higher revenue and earnings than NuCana. China Pharma is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.99M	6.70	-$3.08M	-$0.55	N/A
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A

44.0% of NuCana shares are owned by institutional investors. 6.4% of China Pharma shares are owned by insiders. Comparatively, 31.2% of NuCana shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NuCana has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. China Pharma's return on equity of -63.93% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
NuCana	N/A	-153.61%	-116.03%

China Pharma has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, NuCana has a beta of 2.18, meaning that its share price is 118% more volatile than the broader market.

Summary

NuCana beats China Pharma on 8 of the 13 factors compared between the two stocks.

How does NuCana compare to Briacell Therap?

NuCana (NASDAQ:NCNA) and Briacell Therap (NASDAQ:BCTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends and media sentiment.

NuCana is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$38.71M	-$2.98	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A

Briacell Therap's return on equity of -153.53% beat NuCana's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-153.61%	-116.03%
Briacell Therap	N/A	-153.53%	-129.26%

44.0% of NuCana shares are held by institutional investors. Comparatively, 15.4% of Briacell Therap shares are held by institutional investors. 31.2% of NuCana shares are held by insiders. Comparatively, 0.7% of Briacell Therap shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Briacell Therap had 2 more articles in the media than NuCana. MarketBeat recorded 3 mentions for Briacell Therap and 1 mentions for NuCana. NuCana's average media sentiment score of 1.87 beat Briacell Therap's score of 0.96 indicating that NuCana is being referred to more favorably in the media.

Company	Overall Sentiment
NuCana	Very Positive
Briacell Therap	Positive

NuCana has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.21, suggesting that its share price is 21% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

NuCana beats Briacell Therap on 6 of the 10 factors compared between the two stocks.

Get NuCana News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NCNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NCNA vs. The Competition

Export

Metric	NuCana	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.58M	$3.66B	$6.87B	$12.45B
Dividend Yield	N/A	2.20%	2.67%	6.16%
P/E Ratio	-0.51	20.90	27.51	24.87
Price / Sales	N/A	341.80	540.69	102.84
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	0.20	8.75	11.01	6.54
Net Income	-$38.71M	$23.81M	$3.57B	$336.70M
7 Day Performance	-12.14%	3.64%	2.56%	3.31%
1 Month Performance	-34.76%	1.64%	0.89%	1.68%
1 Year Performance	-86.76%	69.47%	36.84%	31.96%

NuCana Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NCNA NuCana	1.0215 of 5 stars	$1.52 -3.8%	N/A	-90.8%	$6.58M	N/A	N/A	30	Positive News
VTGN VistaGen Therapeutics	2.9753 of 5 stars	$0.62 -7.3%	$0.95 +54.1%	-61.4%	$27.28M	$1.27M	N/A	40	News Coverage Gap Down Trading Halted
BRNS Barinthus Biotherapeutics	2.0984 of 5 stars	$0.72 +8.9%	$4.00 +456.3%	-29.0%	$26.96M	$14.97M	N/A	107	Gap Up
DYAI Dyadic International	3.0435 of 5 stars	$0.74 +1.4%	$3.00 +304.9%	-11.9%	$26.64M	$3.09M	N/A	7	News Coverage Short Interest Decrease
CPHI China Pharma	N/A	$0.66 +2.3%	N/A	-65.7%	$26.54M	$3.99M	N/A	250	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NCNA) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NuCana (NCNA) Competitors

NCNA vs. VTGN, BRNS, DYAI, CPHI, and BCTX

How does NuCana compare to VistaGen Therapeutics?

Summary

How does NuCana compare to Barinthus Biotherapeutics?

Summary

How does NuCana compare to Dyadic International?

Summary

How does NuCana compare to China Pharma?

Summary

How does NuCana compare to Briacell Therap?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCNA vs. The Competition

NuCana Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NuCana (NCNA) Competitors

NCNA vs. VTGN, BRNS, DYAI, CPHI, and BCTX

How does NuCana compare to VistaGen Therapeutics?

Do analysts prefer NCNA or VTGN?

Does the media refer more to NCNA or VTGN?

Which has stronger valuation & earnings, NCNA or VTGN?

Is NCNA or VTGN more profitable?

Do insiders & institutionals hold more shares of NCNA or VTGN?

Which has more volatility and risk, NCNA or VTGN?

Summary

How does NuCana compare to Barinthus Biotherapeutics?

Do insiders & institutionals hold more shares of NCNA or BRNS?

Is NCNA or BRNS more profitable?

Do analysts rate NCNA or BRNS?

Which has more risk and volatility, NCNA or BRNS?

Which has better valuation and earnings, NCNA or BRNS?

Does the media favor NCNA or BRNS?

Summary

How does NuCana compare to Dyadic International?

Do analysts prefer NCNA or DYAI?

Does the media prefer NCNA or DYAI?

Which has more risk & volatility, NCNA or DYAI?

Do institutionals and insiders have more ownership in NCNA or DYAI?

Which has preferable valuation & earnings, NCNA or DYAI?

Is NCNA or DYAI more profitable?

Summary

How does NuCana compare to China Pharma?

Does the media refer more to CPHI or NCNA?

Which has preferable earnings & valuation, CPHI or NCNA?

Do insiders & institutionals hold more shares of CPHI or NCNA?

Do analysts rate CPHI or NCNA?

Is CPHI or NCNA more profitable?

Which has more risk and volatility, CPHI or NCNA?

Summary

How does NuCana compare to Briacell Therap?

Which has better earnings & valuation, NCNA or BCTX?

Is NCNA or BCTX more profitable?

Do institutionals and insiders hold more shares of NCNA or BCTX?

Does the media prefer NCNA or BCTX?

Which has more volatility & risk, NCNA or BCTX?

Do analysts recommend NCNA or BCTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NCNA vs. The Competition

NuCana Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools